The Role of Decidual Natural Killer Cells in Normal Placentation and in the Pathogenesis of Preeclampsia

Journal of Obstetrics and Gynaecology Canada

Volumn 30, Issue 6, 2008, Pages 467-476

  Eastabrook, Genevieve ^a,b   Hu, Yuxiang ^b   von Dadelszen, Peter ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Assisted reproductive technology; Chemokines; Decidua; Interferon type II; Natural killer cells; Placenta; Preeclampsia; Recurrent pregnancy loss; Trophoblasts

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 8; RANTES;

ANGIOGENESIS; ARTICLE; CELL INTERACTION; CELL INVASION; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DECIDUA; EXTRAVILLOUS TROPHOBLAST; FERTILIZATION IN VITRO; IMMUNE DYSREGULATION; IN VITRO STUDY; MURINE MODEL; NATURAL KILLER CELL; PATHOGENESIS; PLACENTA; PLACENTA ACCRETA; PREECLAMPSIA; PREGNANCY TERMINATION; PROTEIN FUNCTION; REPRODUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TREATMENT FAILURE; TROPHOBLAST; ADULT; ANIMAL; CELL COMMUNICATION; CELL CULTURE; CELL MOTION; CYTOLOGY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; IMMUNOLOGY; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; REVIEW;

ADULT; ANIMALS; CELL COMMUNICATION; CELL MOVEMENT; CELLS, CULTURED; DECIDUA; FEMALE; HUMANS; KILLER CELLS, NATURAL; MICE; PLACENTA; PLACENTATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; TROPHOBLASTS;

EID: 53449098975     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32862-6     Document Type: Article

References (102)

1. Brosens I., Dixon H.G., Robertson W.B. Fetal growth retardation and the arteries of the placental bed. Br J Obstet Gynaecol 1977, 84(9):656-663.
2. Khong T.Y., De W.F., Robertson W.B., Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986, 93(10):1049-1059.
3. Norwitz E.R. Defective implantation and placentation: laying the blueprint for pregnancy complications. Reprod Biomed Online 2006, 13(4):591-599.
4. Bulmer J.N. Immune aspects of pathology of the placental bed contributing to pregnancy pathology. Baillieres Clin Obstet Gynaecol 1992, 6(3):461-488.
5. Labarrere C.A., Althabe O.H. Primary chronic abortion, preeclampsia, idiopathic intrauterine growth retardation, hydatidiform mole, and choriocarcinoma: a unifying concept. Am J Reprod Immunol Microbiol 1986, 10(4):156-157.
6. Harma M., Harma M. Defective placentation and resultant oxidative stress play a similar role in complete hydatidiform mole to that in preeclampsia and early pregnancy loss. Med Hypotheses 2006, 66(1):100-102.
7. Ananth C.V., Vintzileos A.M. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol 2006, 195(6):1557-1563.
8. Liston R.M. The path to prevention. J Obstet Gynaecol Can 2005, 27(2):117-121.
9. MacKay A.P., Berg C.J., Atrash H.K. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001, 97(4):533-538.
10. von D.P., Magee L.A., Devarakonda R.M., Hamilton T., Ainsworth L.M., Yin R., et al. The prediction of adverse maternal outcomes in preeclampsia. J Obstet Gynaecol Can 2004, 26(10):871-879.
11. Why mothers die 2000-2002-The sixth report of confidential enquiries into maternal deaths in the United Kingdom 2004, Royal College of Obstetricians and Gynaecologists, London. G. Lewis (Ed.).
12. Wen S.W., Huang L., Liston R., Heaman M., Baskett T., Rusen I.D., et al. Severe maternal morbidity in Canada, 1991-2001. CMAJ 2005, 173(7):759-764.
13. Zhang J., Meikle S., Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy 2003, 22(2):203-212.
14. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol 1992, 99(7):547-553.
15. Ngoc N.T., Merialdi M., bdel-Aleem H., Carroli G., Purwar M., Zavaleta N., et al. Causes of stillbirths and early neonatal deaths: data from 7993 pregnancies in six developing countries. Bull World Health Organ 2006, 84(9):699-705.
16. Romero-Gutierrez G., Espitia-Vera A., de Leon AL Ponce-Ponce, Huerta-Vargas L.F. Risk factors of maternal death in Mexico. Birth 2007, 34(1):21-25.
17. World Health Organization Revised 1990 estimates of maternal mortality: a new approach by WHO and UNICEF 1996, WHO, Geneva.
18. Rusen I.D., Liston R.M. Special report on maternal mortality and severe morbidity in Canada: enhanced surveillance: the path to prevention 2008, Public Health Agency of Canada.
19. Xiong X., Buekens P., Pridjian G., Fraser W.D. Pregnancy-induced hypertension and perinatal mortality. J Reprod Med 2007, 52(5):402-406.
20. Hayter M.A., Anderson L., Claydon J., Magee L.A., Liston R.M., Lee S.K., et al. Variations in early and intermediate neonatal outcomes for inborn infants admitted to a Canadian NICU and born of hypertensive pregnancies. J Obstet Gynaecol Can 2005, 27(1):25-32.
21. Ashkar A.A., Black G.P., Wei Q., He H., Liang L., Head J.R., et al. Assessment of requirements for IL-15 and IFN regulatory factors in uterine NK cell differentiation and function during pregnancy. J Immunol 2003, 171(6):2937-2944.
22. Ashkar A.A., Croy B.A. Functions of uterine natural killer cells are mediated by interferon gamma production during murine pregnancy. Semin Immunol 2001, 13(4):235-241.
23. Croy B.A., He H., Esadeg S., Wei Q., McCartney D., Zhang J., et al. Uterine natural killer cells: insights into their cellular and molecular biology from mouse modelling. Reproduction 2003, 126(2):149-160.
24. Croy B.A., Chantakru S., Esadeg S., Ashkar A.A., Wei Q. Decidual natural killer cells: key regulators of placental development (a review). J Reprod Immunol 2002, 57(1-2):151-168.
25. Parham P. NK cells and trophoblasts: partners in pregnancy. J Exp Med 2004, 200(8):951-955.
26. Ashkar A.A., Di Santo J.P., Croy B.A. Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med 2000, 192(2):259-270.
27. Hanna J., Goldman-Wohl D., Hamani Y., Avraham I., Greenfield C., Natanson-Yaron S., et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006, 12(9):1065-1074.
28. Saito S., Kasahara T., Sakakura S., Enomoto M., Umekage H., Harada N., et al. Interleukin-8 production by CD16-CD56bright natural killer cells in the human early pregnancy decidua. Biochem Biophys Res Commun 1994, 200(1):378-383.
29. Li X.F., Charnock-Jones D.S., Zhang E., Hiby S., Malik S., Day K., et al. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J Clin Endocrinol Metab 2001, 86(4):1823-1834.
30. Hu Y., Dutz J.P., MacCalman C.D., Yong P., Tan R., von D.P. Decidual NK cells alter in vitro first trimester extravillous cytotrophoblast migration: a role for IFN-gamma. J Immunol 2006, 177(12):8522-8530.
31. Koopman L.A., Kopcow H.D., Rybalov B., Boyson J.E., Orange J.S., Schatz F., et al. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med 2003, 198(8):1201-1212.
32. Lopez-Botet M., Moretta L., Strominger J. NK-cell receptors and recognition of MHC class I molecules. Immunol Today 1996, 17(5):212-214.
33. Verma S., Hiby S.E., Loke Y.W., King A. Human decidual natural killer cells express the receptor for and respond to the cytokine interleukin 15. Biol Reprod 2000, 62(4):959-968.
34. Starkey P.M., Sargent I.L., Redman C.W. Cell populations in human early pregnancy decidua: characterization and isolation of large granular lymphocytes by flow cytometry. Immunology 1988, 65(1):129-134.
35. King A. Uterine leukocytes and decidualization. Hum Reprod Update 2000, 6(1):28-36.
36. Moffett-King A., Entrican G., Ellis S., Hutchinson J., Bainbridge D. Natural killer cells and reproduction. Trends Immunol 2002, 23(7):332-333.
37. Peloggia A., Petta C.A., Bahamondes L., Oliveira-Ribeiro M., Zhang J., Salamonsen L.A. Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod 2006, 21(5):1129-1134.
38. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002, 2(9):656-663.
39. Panigel M. The origin and structure of the extraembryonic tissues. The Human Placenta 1993, 3-32. Blackwell Scientific, Oxford. C.W.G. Redman, I.L. Sargent, P.M. Starkey (Eds.).
40. King A., Burrows T.D., Hiby S.E., Bowen J.M., Joseph S., Verma S., et al. Surface expression of HLA-C antigen by human extravillous trophoblast. Placenta 2000, 21(4):376-387.
41. Hiby S.E., Walker J.J., O'Shaughnessy K.M., Redman C.W., Carrington M., Trowsdale J., et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004, 200(8):957-965.
42. Jacobs R., Hintzen G., Kemper A., Beul K., Kempf S., Behrens G., et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001, 31(10):3121-3127.
43. King A., Allan D.S., Bowen M., Powis S.J., Joseph S., Verma S., et al. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol 2000, 30(6):1623-1631.
44. Yelavarthi K.K., Fishback J.L., Hunt J.S. Analysis of HLA-G mRNA in human placental and extraplacental membrane cells by in situ hybridization. J Immunol 1991, 146(8):2847-2854.
45. Rajagopalan S., Bryceson Y.T., Kuppusamy S.P., Geraghty D.E., van der M.A., Joosten I., et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006, 4(1):e9.
46. Rajagopalan S., Long E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999, 189(7):1093-1100.
47. Dietl J., Honig A., Kammerer U., Rieger L. Natural killer cells and dendritic cells at the human feto-maternal interface: an effective cooperation?. Placenta 2006, 27(4-5):341-347.
48. McMaster M.T., Librach C.L., Zhou Y., Lim K.H., Janatpour M.J., DeMars R., et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 1995, 154(8):3771-3778.
49. Goldman-Wohl D.S., Ariel I., Greenfield C., Hochner-Celnikier D., Cross J., Fisher S., et al. Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. Mol Hum Reprod 2000, 6(1):88-95.
50. Lyall F. Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-eclampsia. Aust N Z J Obstet Gynaecol 2006, 46(4):266-273.
51. Lim K.H., Zhou Y., Janatpour M., McMaster M., Bass K., Chun S.H., et al. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. Am J Pathol 1997, 151(6):1809-1818.
52. Fons P., Chabot S., Cartwright J.E., Lenfant F., L'Faqihi F., Giustiniani J., et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006, 108(8):2608-2615.
53. Le B.P., Fons P., Herault J.P., Bono F., Chabot S., Cartwright J.E., et al. Soluble HLA-G and control of angiogenesis. J Reprod Immunol 2007, 76(1-2):17-22.
54. Varla-Leftherioti M., Spyropoulou-Vlachou M., Niokou D., Keramitsoglou T., Darlamitsou A., Tsekoura C., et al. Natural killer (NK) cell receptors' repertoire in couples with recurrent spontaneous abortions. Am J Reprod Immunol 2003, 49(3):183-191.
55. Coulam C.B., Roussev R.G. Correlation of NK cell activation and inhibition markers with NK cytoxicity among women experiencing immunologic implantation failure after in vitro fertilization and embryo transfer. J Assist Reprod Genet 2003, 20(2):58-62.
56. Ntrivalas E.I., Bowser C.R., Kwak-Kim J., Beaman K.D., Gilman-Sachs A. Expression of killer immunoglobulin-like receptors on peripheral blood NK cell subsets of women with recurrent spontaneous abortions or implantation failures. Am J Reprod Immunol 2005, 53(5):215-221.
57. Zhou Y., McMaster M., Woo K., Janatpour M., Perry J., Karpanen T., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002, 160(4):1405-1423.
58. Damsky C.H., Librach C., Lim K.H., Fitzgerald M.L., McMaster M.T., Janatpour M., et al. Integrin switching regulates normal trophoblast invasion. Development 1994, 120(12):3657-3666.
59. Floridon C., Nielsen O., Holund B., Sunde L., Westergaard J.G., Thomsen S.G., et al. Localization of E-cadherin in villous, extravillous and vascular trophoblasts during intrauterine, ectopic and molar pregnancy. Mol Hum Reprod 2000, 6(10):943-950.
60. Aplin J.D. Expression of integrin alpha 6 beta 4 in human trophoblast and its loss from extravillous cells. Placenta 1993, 14(2):203-215.
61. Zhou Y., Fisher S.J., Janatpour M., Genbacev O., Dejana E., Wheelock M., et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?. J Clin Invest 1997, 99(9):2139-2151.
62. Zhou Y., Damsky C.H., Fisher S.J. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. J Clin Invest 1997, 99(9):2152-2164.
63. Aplin J.D. Expression of integrin alpha 6 beta 4 in human trophoblast and its loss from extravillous cells. Placenta 1993, 14(2):203-215.
64. Ashkar A.A., Croy B.A. Interferon-gamma contributes to the normalcy of murine pregnancy. Biol Reprod 1999, 61(2):493-502.
65. Croy B.A., Ashkar A.A., Minhas K., Greenwood J.D. Can murine uterine natural killer cells give insights into the pathogenesis of preeclampsia?. J Soc Gynecol Investig 2000, 7(1):12-20.
66. Croy B.A., Ashkar A.A., Foster R.A., DiSanto J.P., Magram J., Carson D., et al. Histological studies of gene-ablated mice support important functional roles for natural killer cells in the uterus during pregnancy. J Reprod Immunol 1997, 35(2):111-133.
67. Tseng J.J., Chou M.M., Hsieh Y.T., Wen M.C., Ho E.S., Hsu S.L. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 2006, 27(1):70-78.
68. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242.
69. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995, 270(45):27348-27357.
70. Matsubara K., Nagamatsu T., Fujii T., Kozuma S., Taketani Y. Lymphokine-activated killer cells induced from decidual lymphocytes reduce the angiogenic activity of trophoblasts by enhancing the release of soluble fms-like tyrosine kinase-1 from trophoblasts: an implication for the pathophysiology of preeclampsia. J Reprod Immunol 2005, 68(1-2):27-37.
71. Hamai Y., Fujii T., Yamashita T., Nishina H., Kozuma S., Mikami Y., et al. Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of preeclampsia. Am J Reprod Immunol 1997, 38(2):89-93.
72. Kendall R.L., Wang G., Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996, 226(2):324-328.
73. Dimitrakova E.D., Dimitrakov J.D., Karumanchi S.A., Pehlivanov B.K., Milchev N.P., Dimitrakov D.I. Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia. Folia Med (Plovdiv ) 2004, 46(1):19-21.
74. Clark D.E., Smith S.K., He Y., Day K.A., Licence D.R., Corps A.N., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998, 59(6):1540-1548.
75. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111(5):649-658.
76. Magee L.A., Helewa M., Moutquin J.-M., Von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. SOGC Clinical Practice Guideline No. 206, March 2008. J Obstet Gynaecol Can 2008, 30(Suppl 1).
77. Toporsian M., Gros R., Kabir M.G., Vera S., Govindaraju K., Eidelman D.H., et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005, 96(6):684-692.
78. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355(10):992-1005.
79. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12(6):642-649.
80. Drake P.M., Red-Horse K., Fisher S.J. Reciprocal chemokine receptor and ligand expression in the human placenta: implications for cytotrophoblast differentiation. Dev Dyn 2004, 229(4):877-885.
81. Drake P.M., Red-Horse K., Fisher S.J. Chemokine expression and function at the human maternal-fetal interface. Rev Endocr Metab Disord 2002, 3(2):159-165.
82. Red-Horse K., Drake P.M., Fisher S.J. Human pregnancy: the role of chemokine networks at the fetalmaternal interface. Expert Rev Mol Med 2004, 2004:1-14.
83. Red-Horse K., Drake P.M., Gunn M.D., Fisher S.J. Chemokine ligand and receptor expression in the pregnant uterus: reciprocal patterns in complementary cell subsets suggest functional roles. Am J Pathol 2001, 159(6):2199-2213.
84. Thirkill T.L., Lowe K., Vedagiri H., Blankenship T.N., Barakat A.I., Douglas G.C. Macaque trophoblast migration is regulated by RANTES. Exp Cell Res 2005, 305(2):355-364.
85. Hannan N.J., Jones R.L., White C.A., Salamonsen L.A. The chemokines, CX3CL1, CCL14, and CCL4, promote human trophoblast migration at the feto-maternal interface. Biol Reprod 2006, 74(5):896-904.
86. Sato Y., Higuchi T., Yoshioka S., Tatsumi K., Fujiwara H., Fujii S. Trophoblasts acquire a chemokine receptor, CCR1, as they differentiate towards invasive phenotype. Development 2003, 130(22):5519-5532.
87. Lachapelle M.H., Miron P., Hemmings R., Roy D.C., Endometrial T. B, and NK cells in patients with recurrent spontaneous abortion. Altered profile and pregnancy outcome. J Immunol 1996, 156(10):4027-4034.
88. Quenby S., Farquharson R. Uterine natural killer cells, implantation failure and recurrent miscarriage. Reprod Biomed Online 2006, 13(1):24-28.
89. Yamamoto T., Takahashi Y., Kase N., Mori H. Decidual natural killer cells in recurrent spontaneous abortion with normal chromosomal content. Am J Reprod Immunol 1999, 41(5):337-342.
90. Chao K.H., Yang Y.S., Ho H.N., Chen S.U., Chen H.F., Dai H.J., et al. Decidual natural killer cytotoxicity decreased in normal pregnancy but not in anembryonic pregnancy and recurrent spontaneous abortion. Am J Reprod Immunol 1995, 34(5):274-280.
91. Vassiliadou N., Bulmer J.N. Functional studies of human decidua in spontaneous early pregnancy loss: effect of soluble factors and purified CD56+ lymphocytes on killing of natural killer- and lymphokine-activated killer-sensitive targets. Biol Reprod 1998, 58(4):982-987.
92. Tuckerman E., Laird S.M., Prakash A., Li T.C. Prognostic value of the measurement of uterine natural killer cells in the endometrium of women with recurrent miscarriage. Hum Reprod 2007, 22(8):2208-2213.
93. Ledee-Bataille N., Bonnet-Chea K., Hosny G., Dubanchet S., Frydman R., Chaouat G. Role of the endometrial tripod interleukin-18, -15, and -12 in inadequate uterine receptivity in patients with a history of repeated in vitro fertilization-embryo transfer failure. Fertil Steril 2005, 83(3):598-605.
94. Ledee-Bataille N., Dubanchet S., Coulomb-L'hermine A., Durand-Gasselin I., Frydman R., Chaouat G. A new role for natural killer cells, interleukin (IL)-12, and IL-18 in repeated implantation failure after in vitro fertilization. Fertil Steril 2004, 81(1):59-65.
95. Matteo M.G., Greco P., Rosenberg P., Mestice A., Baldini D., Falagario T., et al. Normal percentage of CD56bright natural killer cells in young patients with a history of repeated unexplained implantation failure after in vitro fertilization cycles. Fertil Steril 2007, 88(4):990-993.
96. Dong M., He J., Wang Z., Xie X., Wang H. Placental imbalance of Th1- and Th2-type cytokines in preeclampsia. Acta Obstet Gynecol Scand 2005, 84(8):788-793.
97. Wilczynski J.R., Tchorzewski H., Banasik M., Glowacka E., Wieczorek A., Lewkowicz P., et al. Lymphocyte subset distribution and cytokine secretion in third trimester decidua in normal pregnancy and preeclampsia. Eur J Obstet Gynecol Reprod Biol 2003, 109(1):8-15.
98. Borzychowski A.M., Croy B.A., Chan W.L., Redman C.W., Sargent I.L. Changes in systemic type 1 and type 2 immunity in normal pregnancy and pre-eclampsia may be mediated by natural killer cells. Eur J Immunol 2005, 35(10):3054-3063.
99. Bachmayer N., Rafik H.R., Liszka L., Bremme K., Sverremark-Ekstrom E. Aberrant uterine natural killer (NK)-cell expression and altered placental and serum levels of the NK-cell promoting cytokine interleukin-12 in pre-eclampsia. Am J Reprod Immunol 2006, 56(5-6):292-301.
100. Chaillet N., Dumont A. Evidence-based strategies for reducing cesarean section rates: a meta-analysis. Birth 2007, 34(1):53-64.
101. Liu S., Rusen I.D., Joseph K.S., Liston R., Kramer M.S., Wen S.W., et al. Recent trends in caesarean delivery rates and indications for caesarean delivery in Canada. J Obstet Gynaecol Can 2004, 26(8):735-742.
102. Gielchinsky Y., Rojansky N., Fasouliotis S.J., Ezra Y. Placenta accreta-summary of 10 years: a survey of 310 cases. Placenta 2002, 23(2-3):210-214.